Kumon, H
Ariyoshi, Y
Sasaki, K
Sadahira, T
Araki, M
Ebara, S
Yanai, H
Watanabe, M
Nasu, Y
Article History
Received: 5 September 2016
Revised: 14 September 2016
Accepted: 23 September 2016
First Online: 21 October 2016
Competing interests
: Okayama University and Momotaro-Gene Inc., a startup biotech company from the Okayama University, holds the patents of the Ad-REIC agent and develops the agent as a cancer therapeutic medicine. HK, MW and YN demonstrated the utility of the agent and also own stocks in Momotaro-Gene Inc. HK is the Chief Scientific Officer of Momotaro-Gene Inc. Okayama University and Momotaro-Gene Inc. are working together on the development of the Ad-REIC agent. Okayama University received cGMP-grade products of Ad5-REIC from Momotaro-Gene Inc. to perform clinical studies for the treatment of cancer patients.